{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:03:18Z","timestamp":1789750998102,"version":"4.0.1"},"reference-count":42,"publisher":"e-Century Publishing Corporation","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Nucl Med Mol Imaging"],"DOI":"10.62347\/obzs8887","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T05:34:36Z","timestamp":1730352876000},"page":"327-336","source":"Crossref","is-referenced-by-count":6,"title":["Radiosynthesis and evaluation of a novel 18F-labeled tracer for PET imaging of glycogen synthase kinase 3"],"prefix":"10.62347","volume":"14","author":[{"given":"Zhiwei","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Woodgett JR. Judging a protein by more than its name: GSK-3. Sci STKE 2001; 2001: re12.","DOI":"10.1126\/scisignal.1002001re12"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","article-title":"Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases","volume":"148","author":"Beurel","year":"2015","unstructured":"Beurel E, Grieco SF and Jope RS. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther 2015; 148: 114-31.","journal-title":"Pharmacol Ther"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1002\/j.1460-2075.1990.tb07419.x","article-title":"Molecular cloning and expression of glycogen synthase kinase-3\/factor A","volume":"9","author":"Woodgett","year":"1990","unstructured":"Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3\/factor A. EMBO J 1990; 9: 2431-8.","journal-title":"EMBO J"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/00005072-199701000-00007","article-title":"Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain","volume":"56","author":"Pei","year":"1997","unstructured":"Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K and Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol 1997; 56: 70-8.","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0891-0618(99)00012-5","article-title":"Developmental expression and localization of glycogen synthase kinase-3β in rat brain","volume":"16","author":"Leroy","year":"1999","unstructured":"Leroy K and Brion JP. Developmental expression and localization of glycogen synthase kinase-3β in rat brain. J Chem Neuroanat 1999; 16: 279-93.","journal-title":"J Chem Neuroanat"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0301-0082(01)00011-9","article-title":"The multifaceted roles of glycogen synthase kinase 3β in cellular signaling","volume":"65","author":"Grimes","year":"2001","unstructured":"Grimes CA and Jope RS. The multifaceted roles of glycogen synthase kinase 3β in cellular signaling. Prog Neurobiol 2001; 65: 391-426.","journal-title":"Prog Neurobiol"},{"key":"ref6","unstructured":"Adam RC. Regulation of cell fate in the brain by GSK3. In: Sabine WG, editors. Trends in Cell Signaling Pathways in Neuronal Fate Decision. Rijeka: IntechOpen; 2013. pp. 6."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"189728","DOI":"10.4061\/2011\/189728","article-title":"GSK3 function in the brain during development, neuronal plasticity, and neurodegeneration","volume":"2011","author":"Salcedo-Tello","year":"2011","unstructured":"Salcedo-Tello P, Ortiz-Matamoros A and Arias C. GSK3 function in the brain during development, neuronal plasticity, and neurodegeneration. Int J Alzheimers Dis 2011; 2011: 189728.","journal-title":"Int J Alzheimers Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1093\/hmg\/dds533","article-title":"Dual effects of increased glycogen synthase kinase-3β activity on adult neurogenesis","volume":"22","author":"Fuster-Matanzo A","year":"2013","unstructured":"Fuster-Matanzo A, Llorens-Martín M, Sirerol-Piquer MS, García-Verdugo JM, Avila J and Hernández F. Dual effects of increased glycogen synthase kinase-3β activity on adult neurogenesis. Hum Mol Genet 2013; 22: 1300-15.","journal-title":"Hum Mol Genet"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1161\/CIRCRESAHA.116.303613","article-title":"The GSK-3 family as therapeutic target for myocardial diseases","volume":"116","author":"Lal","year":"2015","unstructured":"Lal H, Ahmad F, Woodgett J and Force T. The GSK-3 family as therapeutic target for myocardial diseases. Circ Res 2015; 116: 138-49.","journal-title":"Circ Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.18632\/oncotarget.2037","article-title":"GSK-3 as potential target for therapeutic intervention in cancer","volume":"5","author":"JA","year":"2014","unstructured":"McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Sokolosky M, Abrams SL, Montalto G, D’Assoro AB, Libra M, Nicoletti F, Maestro R, Basecke J, Rakus D, Gizak A, Demidenko ZN, Cocco L, Martelli AM and Cervello M. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget 2014; 5: 2881-911.","journal-title":"Oncotarget"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"13470","DOI":"10.1074\/jbc.M110.127969","article-title":"Distinct molecular regulation of glycogen synthase kinase-3α isozyme controlled by its N-terminal region: functional role in calcium\/calpain signaling","volume":"286","author":"Azoulay-Alfaguter","year":"2011","unstructured":"Azoulay-Alfaguter I, Yaffe Y, Licht-Murava A, Urbanska M, Jaworski J, Pietrokovski S, Hirschberg K and Eldar-Finkelman H. Distinct molecular regulation of glycogen synthase kinase-3α isozyme controlled by its N-terminal region: functional role in calcium\/calpain signaling. J Biol Chem 2011; 286: 13470-80.","journal-title":"J Biol Chem"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2174\/2211550111201010080","article-title":"Structural and functional relationships between GSK3α and GSK3β proteins","volume":"1","author":"Laura Sayas","year":"2012","unstructured":"Laura Sayas C, Jurado J, Avila J and Villanueva N. Structural and functional relationships between GSK3α and GSK3β proteins. Curr Biotechnol 2012; 1: 80-7.","journal-title":"Curr Biotechnol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0891-0618(02)00014-5","article-title":"Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain","volume":"23","author":"Yao","year":"2002","unstructured":"Yao HB, Shaw PC, Wong CC and Wan DC. Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain. J Chem Neuroanat 2002; 23: 291-7.","journal-title":"J Chem Neuroanat"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1034\/j.1399-3011.1999.00083.x","article-title":"Expression analysis of glycogen synthase kinase-3 in human tissues","volume":"54","author":"Lau","year":"1999","unstructured":"Lau KF, Miller CC, Anderton BH and Shaw PC. Expression analysis of glycogen synthase kinase-3 in human tissues. J Pept Res 1999; 54: 85-91.","journal-title":"J Pept Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","article-title":"The GSK3 hypothesis of Alzheimer’s disease","volume":"104","author":"Hooper","year":"2008","unstructured":"Hooper C, Killick R and Lovestone S. The GSK3 hypothesis of Alzheimer’s disease. J Neurochem 2008; 104: 1433-9.","journal-title":"J Neurochem"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/rns.2011.061","article-title":"GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease","volume":"23","author":"Gao","year":"2011","unstructured":"Gao C, Hölscher C, Liu Y and Li L. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev Neurosci 2011; 23: 1-11.","journal-title":"Rev Neurosci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s11064-006-9128-5","article-title":"Glycogen synthase kinase-3 (GSK3): infl ammation, diseases, and therapeutics","volume":"32","author":"RS","year":"2007","unstructured":"Jope RS, Yuskaitis CJ and Beurel E. Glycogen synthase kinase-3 (GSK3): infl ammation, diseases, and therapeutics. Neurochem Res 2007; 32: 577-95.","journal-title":"Neurochem Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.arr.2012.06.003","article-title":"Tau protein kinases: involvement in Alzheimer’s disease","volume":"12","author":"Martin","year":"2013","unstructured":"Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C and Terro F. Tau protein kinases: involvement in Alzheimer’s disease. Ageing Res Rev 2013; 12: 289-309.","journal-title":"Ageing Res Rev"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nrd1415","article-title":"GSK3 inhibitors: development and therapeutic potential","volume":"3","author":"Cohen","year":"2004","unstructured":"Cohen P and Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 2004; 3: 479-87.","journal-title":"Nat Rev Drug Discov"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"792364","DOI":"10.3389\/fnmol.2021.792364","article-title":"Glycogen synthase kinase-3 inhibitors: preclinical and clinical focus on CNS-A decade onward","volume":"14","author":"Arciniegas Ruiz","year":"2022","unstructured":"Arciniegas Ruiz SM and Eldar-Finkelman H. Glycogen synthase kinase-3 inhibitors: preclinical and clinical focus on CNS-A decade onward. Front Mol Neurosci 2022; 14: 792364.","journal-title":"Front Mol Neurosci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/13543776.2020.1815706","article-title":"Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2016-2019)","volume":"30","author":"Roca","year":"2020","unstructured":"Roca C and Campillo NE. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2016-2019). Expert Opin Ther Pat 2020; 30: 863-72.","journal-title":"Expert Opin Ther Pat"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/jnc.12203","article-title":"AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans","volume":"125","author":"Georgievska","year":"2013","unstructured":"Georgievska B, Sandin J, Doherty J, Mörtberg A, Neelissen J, Andersson A, Gruber S, Nilsson Y, Schött P, Arvidsson PI, Hellberg S, Osswald G, Berg S, Fälting J and Bhat RV. AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans. J Neurochem 2013; 125: 446-56.","journal-title":"J Neurochem"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A phase II trial of tideglusib in Alzheimer’s disease","volume":"45","author":"Lovestone","year":"2015","unstructured":"Lovestone S, Boada M, Dubois B, Hüll M, Rinne JO, Huppertz HJ, Calero M, Andrés MV, Gómez-Carrillo B, León T and del Ser T; ARGO investigators. A phase II trial of tideglusib in Alzheimer’s disease. J Alzheimers Dis 2015; 45: 75-88.","journal-title":"J Alzheimers Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.3109\/10428194.2015.1122781","article-title":"An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia","volume":"57","author":"Rizzieri","year":"2016","unstructured":"Rizzieri DA, Cooley S, Odenike O, Moonan L, Chow KH, Jackson K, Wang X, Brail L and Borthakur G. An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. Leuk Lymphoma 2016; 57: 1800-6.","journal-title":"Leuk Lymphoma"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1042\/BST0371133","article-title":"Validating GSK3 as an in vivo target of lithium action","volume":"37","author":"O&#x2019","year":"2009","unstructured":"O’Brien WT and Klein PS. Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans 2009; 37: 1133-8.","journal-title":"Biochem Soc Trans"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1038\/s41467-023-36377-4","article-title":"Radiochemistry for positron emission tomography","volume":"14","author":"Rong","year":"2023","unstructured":"Rong J, Haider A, Jeppesen TE, Josephson L and Liang SH. Radiochemistry for positron emission tomography. Nat Commun 2023; 14: 3257.","journal-title":"Nat Commun"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/anie.201805501","article-title":"Chemistry for positron emission tomography: recent advances in 11C-, 18F-, 13N-, and 15O-labeling reactions","volume":"58","author":"Deng","year":"2019","unstructured":"Deng X, Rong J, Wang L, Vasdev N, Zhang L, Josephson L and Liang SH. Chemistry for positron emission tomography: recent advances in 11C-, 18F-, 13N-, and 15O-labeling reactions. Angew Chem Int Ed Engl 2019; 58: 2580-605.","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.1016\/j.bmcl.2005.08.037","article-title":"Synthesis and ex vivo evaluation of carbon-11 labelled N-(4-methoxybenzyl)-N’-(5-nitro-1,3-thiazol-2-yl)urea ([11C]AR-A014418): a radiolabelled glycogen synthase kinase-3β specific inhibitor for PET studies","volume":"15","author":"Vasdev","year":"2005","unstructured":"Vasdev N, Garcia A, Stableford WT, Young AB, Meyer JH, Houle S and Wilson AA. Synthesis and ex vivo evaluation of carbon-11 labelled N-(4-methoxybenzyl)-N’-(5-nitro-1,3-thiazol-2-yl)urea ([11C]AR-A014418): a radiolabelled glycogen synthase kinase-3β specific inhibitor for PET studies. Bioorg Med Chem Lett 2005; 15: 5270-3.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.nucmedbio.2014.03.025","article-title":"Synthesis and evaluation of [11C]PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3β (GSK-3β)","volume":"41","author":"Cole","year":"2014","unstructured":"Cole EL, Shao X, Sherman P, Quesada C, Fawaz MV, Desmond TJ and Scott PJ. Synthesis and evaluation of [11C]PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3β (GSK-3β). Nucl Med Biol 2014; 41: 507-12.","journal-title":"Nucl Med Biol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1016\/j.bmcl.2015.05.085","article-title":"Radiosynthesis and preliminary PET evaluation of glycogen synthase kinase 3β (GSK-3β) inhibitors containing [11C]methylsulfanyl, [11C]methylsulfinyl or [11C]methylsulfonyl groups","volume":"25","author":"Kumata","year":"2015","unstructured":"Kumata K, Yui J, Xie L, Zhang Y, Nengaki N, Fujinaga M, Yamasaki T, Shimoda Y and Zhang MR. Radiosynthesis and preliminary PET evaluation of glycogen synthase kinase 3β (GSK-3β) inhibitors containing [11C]methylsulfanyl, [11C]methylsulfinyl or [11C]methylsulfonyl groups. Bioorg Med Chem Lett 2015; 25: 3230-3.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.bmcl.2010.11.026","article-title":"The first synthesis of [11C]SB-216763, a new potential PET agent for imaging of glycogen synthase kinase-3 (GSK-3)","volume":"21","author":"Wang","year":"2011","unstructured":"Wang M, Gao M, Miller KD, Sledge GW, Hutchins GD and Zheng QH. The first synthesis of [11C]SB-216763, a new potential PET agent for imaging of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett 2011; 21: 245-9.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1021\/acsmedchemlett.5b00044","article-title":"Synthesis and initial in vivo studies with [11C]SB-216763: the first radiolabeled brain penetrative inhibitor of GSK-3","volume":"6","author":"Li","year":"2015","unstructured":"Li L, Shao X, Cole EL, Ohnmacht SA, Ferrari V, Hong YT, Williamson DJ, Fryer TD, Quesada CA, Sherman P, Riss PJ, Scott PJ and Aigbirhio FI. Synthesis and initial in vivo studies with [11C]SB-216763: the first radiolabeled brain penetrative inhibitor of GSK-3. ACS Med Chem Lett 2015; 6: 548-52.","journal-title":"ACS Med Chem Lett"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1021\/acsmedchemlett.6b00405","article-title":"Development of [18F]Maleimide-based glycogen synthase kinase-3β ligands for positron emission tomography imaging","volume":"8","author":"Hu","year":"2017","unstructured":"Hu K, Patnaik D, Collier TL, Lee KN, Gao H, Swoyer MR, Rotstein BH, Krishnan HS, Liang SH, Wang J, Yan Z, Hooker JM, Vasdev N, Haggarty SJ and Ngai MY. Development of [18F]Maleimide-based glycogen synthase kinase-3β ligands for positron emission tomography imaging. ACS Med Chem Lett 2017; 8: 287-92.","journal-title":"ACS Med Chem Lett"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"9601","DOI":"10.1002\/anie.201603797","article-title":"Discovery of a highly selective glycogen synthase kinase-3 inhibitor (PF-04802367) that modulates tau phosphorylation in the brain: translation for PET neuroimaging","volume":"55","author":"Liang","year":"2016","unstructured":"Liang SH, Chen JM, Normandin MD, Chang JS, Chang GC, Taylor CK, Trapa P, Plummer MS, Para KS, Conn EL, Lopresti-Morrow L, Lanyon LF, Cook JM, Richter KE, Nolan CE, Schachter JB, Janat F, Che Y, Shanmugasundaram V, Lefker BA, Enerson BE, Livni E, Wang L, Guehl NJ, Patnaik D, Wagner FF, Perlis R, Holson EB, Haggarty SJ, El Fakhri G, Kurumbail RG and Vasdev N. Discovery of a highly selective glycogen synthase kinase-3 inhibitor (PF-04802367) that modulates tau phosphorylation in the brain: translation for PET neuroimaging. Angew Chem Int Ed Engl 2016; 55: 9601-5.","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"9600","DOI":"10.1021\/acs.jmedchem.9b01030","article-title":"Structural basis for achieving GSK-3β inhibition with high potency, selectivity, and brain exposure for positron emission tomography imaging and drug discovery","volume":"62","author":"Bernard-Gauthier","year":"2019","unstructured":"Bernard-Gauthier V, Mossine AV, Knight A, Patnaik D, Zhao WN, Cheng C, Krishnan HS, Xuan LL, Chindavong PS, Reis SA, Chen JM, Shao X, Stauff J, Arteaga J, Sherman P, Salem N, Bonsall D, Amaral B, Varlow C, Wells L, Martarello L, Patel S, Liang SH, Kurumbail RG, Haggarty SJ, Scott PJH and Vasdev N. Structural basis for achieving GSK-3β inhibition with high potency, selectivity, and brain exposure for positron emission tomography imaging and drug discovery. J Med Chem 2019; 62: 9600-17.","journal-title":"J Med Chem"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/ph16020194","article-title":"In vivo imaging and kinetic modeling of novel glycogen synthase kinase-3 radiotracers [11C]OCM-44 and [18F]OCM-50 in non-human primates","volume":"16","author":"Smart","year":"2023","unstructured":"Smart K, Zheng MQ, Holden D, Felchner Z, Zhang L, Han Y, Ropchan J, Carson RE, Vasdev N and Huang Y. In vivo imaging and kinetic modeling of novel glycogen synthase kinase-3 radiotracers [11C]OCM-44 and [18F]OCM-50 in non-human primates. Pharmaceuticals (Basel) 2023; 16: 194.","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.bmcl.2019.01.033","article-title":"Radiosynthesis and evaluation of [11C]CMP, a high affinity GSK3 ligand","volume":"29","author":"Prabhakaran","year":"2019","unstructured":"Prabhakaran J, Sai KKS, Sattiraju A, Mintz A, Mann JJ and Kumar JSD. Radiosynthesis and evaluation of [11C]CMP, a high affinity GSK3 ligand. Bioorg Med Chem Lett 2019; 29: 778-81.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.bmcl.2017.01.041","article-title":"Synthesis of carbon-11-labeled isonicotinamides as new potential PET agents for imaging of GSK-3 enzyme in Alzheimer’s disease","volume":"27","author":"Gao","year":"2017","unstructured":"Gao M, Wang M and Zheng QH. Synthesis of carbon-11-labeled isonicotinamides as new potential PET agents for imaging of GSK-3 enzyme in Alzheimer’s disease. Bioorg Med Chem Lett 2017; 27: 740-3.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1021\/acs.molpharmaceut.0c01133","article-title":"Novel 18F-labeled isonicotinamide-based radioligands for positron emission tomography imaging of glycogen synthase kinase-3β","volume":"18","author":"Zhong","year":"2021","unstructured":"Zhong Y, Yang S, Cui J, Wang J, Li L, Chen Y, Chen J, Feng P, Huang S, Li H, Han Y, Tang G and Hu K. Novel 18F-labeled isonicotinamide-based radioligands for positron emission tomography imaging of glycogen synthase kinase-3β. Mol Pharm 2021; 18: 1277-84.","journal-title":"Mol Pharm"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"15960","DOI":"10.1038\/s41598-024-65943-z","article-title":"Synthesis and preliminary evaluation of novel PET probes for GSK-3 imaging","volume":"14","author":"Gundam","year":"2024","unstructured":"Gundam SR, Bansal A, Kethamreddy M, Ghatamaneni S, Lowe VJ, Murray ME and Pandey MK. Synthesis and preliminary evaluation of novel PET probes for GSK-3 imaging. Sci Rep 2024; 14: 15960.","journal-title":"Sci Rep"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1021\/acs.jmedchem.5b01550","article-title":"Discovery of isonicotinamides as highly selective, brain penetrable, and orally active glycogen synthase kinase-3 inhibitors","volume":"59","author":"Luo","year":"2016","unstructured":"Luo G, Chen L, Burton CR, Xiao H, Sivaprakasam P, Krause CM, Cao Y, Liu N, Lippy J, Clarke WJ, Snow K, Raybon J, Arora V, Pokross M, Kish K, Lewis HA, Langley DR, Macor JE and Dubowchik GM. Discovery of isonicotinamides as highly selective, brain penetrable, and orally active glycogen synthase kinase-3 inhibitors. J Med Chem 2016; 59: 1041-51.","journal-title":"J Med Chem"}],"container-title":["American Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajnmmi\/14\/5\/ajnmmi0159323.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:58:02Z","timestamp":1766023082000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajnmmi\/14\/5\/ajnmmi0159323.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/obzs8887","relation":{},"ISSN":["2160-8407"],"issn-type":[{"value":"2160-8407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}